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Abstract
Thrombosis is common in ovarian cancer. However, the interaction of platelets with ovarian cancer cells has not been
critically examined. To address this, we investigated platelet interactions in a range of ovarian cancer cell lines with different
metastatic potentials [HIO-80, 59M, SK-OV-3, A2780, A2780cis]. Platelets adhered to ovarian cancer cells with the most
significant adhesion to the 59M cell line. Ovarian cancer cells induced platelet activation [P-selectin expression] in a dose
dependent manner, with the most significant activation seen in response to the 59M cell line. The platelet antagonists
[cangrelor, MRS2179, and apyrase] inhibited 59M cell induced activation suggesting a P2Y12 and P2Y1 receptor mediated
mechanism of platelet activation dependent on the release of ADP by 59M cells. A2780 and 59M cells potentiated PAR-1,
PAR-4, and TxA2 receptor mediated platelet activation, but had no effect on ADP, epinephrine, or collagen induced
activation. Analysis of gene expression changes in ovarian cancer cells following treatment with washed platelets or platelet
releasate showed a subtle but valid upregulation of anti-apoptotic, anti-autophagy pro-angiogenic, pro-cell cycle and
metabolic genes. Thus, ovarian cancer cells with different metastatic potential adhere and activate platelets differentially
while both platelets and platelet releasate mediate pro-survival and pro-angiogenic signals in ovarian cancer cells.
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Introduction
Ovarian cancer is the fifth leading cause of cancer related
deaths in women [1]. It is the most common gynaecologic
malignancy and has the highest fatality to case ratio of all
gynaecologic malignancies. The poor survival rate is the result of
late stage diagnoses. Most patients are asymptomatic until the
disease has metastasised [2]. Spread of ovarian cancer has been
considered to occur primarily in the peritoneum [3]. However,
autopsy and imaging studies [4], as well as evidence for the
presence of micrometastases in the bone aspirates of early stage
ovarian cancer patients [5] suggest that hematogenous metastasis
is more common than previously thought.
During hematogenous dissemination, the ability of circulating
tumour cells to interact with platelets is believed to promote their
survival within the circulation and therefore facilitate metastasis.
Pre-clinical animal experiments have demonstrated that pharma-
cologically [6] or genetically [7] induced thrombocytopenia, as
well as defects in platelet function [7–10] are associated with
reduced metastasis. The interaction of cancer cells with platelets is
believed to confer a number of advantages that promote successful
metastasis, including protection from immunological assault and
evasion of immune surveillance [11,12], the release of growth,
angiogenic, and vascular permeability factors during activation
and degranulation [13].
Thrombosis and thrombocytosis are frequent complications of
ovarian cancer and are associated with poor prognosis [14–16],
highlighting the importance of platelets in the pathology of ovarian
cancer. However, the interaction between platelets and ovarian
cancer cells has not been well studied. In this study, we aimed to
characterise the interaction of platelets with ovarian cells, using a
normal ovarian cell line [HIO-80] and ovarian cancer cells lines
with different biological properties and metastatic potentials [59M,
SK-OV-3, A2780, and A2780cis].
Firstly, we studied platelet adhesion to ovarian cancer cells
under static conditions to determine if an adhesive interaction
between platelets and ovarian cancer cells exists. Secondly, we
assessed the ability of ovarian cancer cells to induce platelet
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lishing that platelets adhere to ovarian cancer cells, and ovarian
cancer cells are capable of inducing platelet activation and
degranulation, we next assessed gene expression changes at the
transcriptome level in ovarian cancer cells treated with platelets or
platelet releasate. Our results show differential interactions
between platelets and ovarian cancer cell lines, not only in terms
of platelet adhesion and activation, but also in gene expression
changes in cancer cells treated with washed platelets or platelet
releasate. Multiple interactions occur between platelets and
ovarian cancer cells involving factors released by platelets and
cancer cells, as well as direct platelet–ovarian cell interactions.
This interaction results in a pro-survival, pro-angiogenic signal for
the ovarian cancer cell.
Methods
Ethics statement
Blood collection for this study was approved by the Royal
College of Surgeons in Ireland ethics committee and written
informed consent was obtained from all donors prior to
phlebotomy.
Reagents
All reagents were purchased from Sigma-Aldrich [St Louis,
MO, USA] unless otherwise indicated. Collagen [soluble calf
skin], Adenosine-59-Diphosphate, Epinephrine, and Arachidonic
Acid were obtained from BioData [Horsham, PA, USA]. Alexa
Fluor-488-labelled Phalloidin, Calcein AM, and fibrinogen were
obtained from Invitrogen [Carlsbad, CA, USA]. Phycoerythrin
[PE]-labelled anti human P-selectin [mouse IgG], PE-labelled
mouse IgG isotype control, and PE-labelled anti human CD42a
[mouse IgG] antibodies were purchased from BD Pharmingen
[San Diego, CA, USA].
Cell lines
A selection of ovarian cell lines of epithelial origin were chosen
for inclusion in this study as epithelial ovarian cancers are the most
common histological type. HIO-80 [a gift from the Fox Chase
Cancer Center, Philadelphia, PA] represents a non-tumorigenic
normal human ovarian epithelial cell line, which has been
immortalised by transfection with a plasmid encoding for the
SV40 large T gene. The HIO-80 cells were maintained in a 1:1
mixture of medium 199 and MCDB-105 supplemented with 10%
fetal bovine serum, 2 mM L-glutamine, 100 units/ml penicillin,
100 ug/ml streptomycin and 0.2 IU/ml of recombinant human
insulin as recommended by Fox Chase. 59M [European collection
of cell cultures (ECACC), Salisbury, UK] represents a tumorigenic
human ovarian epithelial carcinoma of endometrioid type with
clear cell components, originally isolated from ascites of a 65 year
old patient with metastatic ovarian cancer. 59M cells were
maintained in DMEM, 1 g glucose/L, supplemented with 10%
fetal bovine serum, 2 mM L-glutamine, 100 units/ml penicillin,
and 100 ug/ml streptomycin as recommended by ECACC. SK-
OV-3 [American Type Culture Collection (ATCC), Manassas,
VA, USA] represents a tumorigenic human ovarian epithelial
adenocarcinoma, originally isolated from ascites of a 64 year old
patient with metastatic ovarian cancer. SK-OV-3 was cultured
with McCoy’s 5A media, supplemented with 10% fetal bovine
serum [Invitrogen, The Netherlands], 100 units/ml penicillin and
100 ug/ml streptomycin as recommended by ATCC. A2780
[ECACC, Salisbury, UK] is derived from an ovarian serous
epithelial tumour tissue in an untreated patient. The cisplatin-
resistant cell line A2780cis was developed by chronic exposure of
the parent cisplatin-sensitive A2780 cell line to increasing
concentrations of cisplatin. Both cell lines were maintained in
RPMI 1640 medium supplemented with 10% fetal bovine serum,
2 mM L-glutamine, 100 units/ml penicillin and 100 ug/ml
streptomycin as recommended by ECACC. All cell lines were
grown in standard conditions in a humidified atmosphere
containing 5% CO2 at 37uC.
Platelet preparation
Blood was obtained from healthy donors who had not taken
medications known to affect platelet function for at least 10 days.
Blood was collected by venipuncture through a 19-gauge butterfly
needle without a tourniquet, to avoid platelet activation. Platelets
were prepared as previously described [17]. In brief, for the
preparation of platelet-rich plasma [PRP], blood was collected into
a syringe containing 3.2% trisodium citrate as anticoagulant [10%
vol/vol, then centrifuged at 170 g for 10 minutes at room
temperature. For the preparation of washed platelets, blood was
collected into Acid-Citrate-Dextrose [ACD: 38 mM citric acid,
75 mM sodium citrate, 124 mM D-glucose] as anticoagulant
[15% vol/vol]. Blood was centrifuged at 170 g for 10 minutes at
room temperature. PRP was acidified to pH 6.5 with ACD, and
PGE1 [1 mM] was added to avoid platelet activation during
centrifugation. Platelets were pelleted by centrifugation at 720 g
for 10 minutes. The supernatant was removed and the platelet
pellet was resuspended in JNL buffer [130 mM NaCl, 10 mM
sodium citrate, 9 mM NaHCO3, 6 mM D-glucose, and 0.9 mM
MgCl2, 0.81 mM KH2PO4, and 10 mM Tris, pH 7.4] to a
concentration of 2.5610
8/mL and supplemented with 1.8 mM
CaCl2.
Platelet adhesion assay
The platelet adhesion assay was performed as previously
described [18]. In brief, ovarian cells were seeded in a 96 well
plate [Nunc, Thermo Fisher Scientific, Braunschweig, Germany]
at a concentration of 5610
4/ml and grown until confluent.
Washed platelets [1.5610
8/ml] preloaded with Calcein AM
[2 mg/ml] were allowed to adhere to the cells for 45 minutes at
37uC. The total fluorescence [485/535 nm] per well was
measured using a Wallac 1420 Victor2
TM multilabel counter
[Perkin Elmer, Waltham, MA., USA] plate reader. The plate was
washed three times, 100 ml of JNL was added to each well of the
plate, and the remaining fluorescence was read. % Platelet
adhesion was calculated as [remaining fluorescence – blank]/[total
fluorescence – blank] 6100. Platelet adhesion to ovarian cells was
imaged by fluorescence microscopy. When confluent, cells were
detached with 7 mM EDTA in Dulbecco’s PBS, washed twice,
and resuspended in JNL supplemented with 1.8 mM CaCl2. Cells
[1610
5/ml] were incubated on a BSA coated poly-L-lysine slide
for 45 minutes at 37uC. Following adhesion, washed platelets
[50610
6/ml] were added to the slide and incubated for 45 minutes
at 37uC. Samples were fixed with 3.7% paraformaldehyde for 15
minutes at room temperature and permeabilised with 0.1% Triton
X-100. Platelets and ovarian cells were stained with Alexa Fluor-
488 Phalloidin [41.25 nM,] for 15 minutes at room temperature.
Platelets were specifically stained with phycoerythrin labelled anti-
human CD42a antibody [1.25 mg/ml] for 2 hours at 37uC. The
slides were mounted and imaged by fluorescence microscopy.
Platelet activation
The ability of ovarian cancer cells to induce platelet activation
(P-selectin expression) was assessed by a flow cytometry based
assay modified from Nylander et al [19]. In a total reaction volume
of 100 ml, 10 ml of PRP was incubated with ovarian cancer cells
Platelets and Ovarian Cancer
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6/ml,] in the presence of a PE-labelled anti human P-
selectin antibody [1.25 mg/ml] or an appropriate isotype control
[1.25 mg/ml]. All incubations were performed at room temper-
ature for 15 minutes. The reaction was then terminated with 1 ml
of JNL buffer prior to analysis by flow cytometry. Samples were
analysed using a BD FACS Calibur [Becton Dickinson, Palo Alto,
CA, USA] within 1 hour. The instrument was set to measure size
[forward scatter, FSC], granularity [side scatter, SSC] and cell
fluorescence. Using a log FSC vs. log SSC dot plot, a two
dimensional analysis gate was drawn around the platelet
population, and a fluorescence histogram [log FL2 vs. count]
was obtained for 10000 platelet events for each sample. Data was
analysed using CellQuest Pro software and expressed as
percentage of platelets that were P-selectin positive relative to
the isotype control.
Isolation of platelet releasate
Washed platelets [2.5610
8/ml] were stimulated with both
TRAP [Thrombin receptor activating peptide, 20 mM] and
Collagen [190 mg/ml] and stirred in a BioData PAP-4 light
transmission aggregometer [Horsham, PA, USA] at 37uC for 15
minutes. The platelet aggregate was centrifuged at 720 g for 10
minutes. The supernatant was then aspirated and filtered through
a syringe filter with a 0.22 mm PVDF membrane to remove
platelet microparticles.
MTT assay
To optimise the concentration of platelet releasate for tumour
cell exposure, a series of MTT cell proliferation assays [Roche
Diagnostics Ltd, United Kingdom] were performed according to
the manufacturer’s instructions to determine the maximum
concentration that could be applied to cells without negatively
impacting on cell growth or survival. Cells were seeded into 96-
well cell culture plates at 2610
4 cells/well and cultured for
24 hours to allow cell attachment. Once attached to the plates,
growth media was aspirated and cells were briefly washed with 200
ml of pre warmed PBS. Cells were then exposed to serial dilutions
of platelet releasate from 1:10 to 1:10,000 in full media, serum free
media or JNL buffer to allow optimisation of concentration to be
used in subsequent gene expression based studies.
Washed platelet/platelet releasate exposure for gene
expression analysis
The optimal concentration of platelet releasate [determined by
MTT] was applied to the cell lines and the levels of apoptosis were
compared against cells grown in full media only using a Roche
Apodirect TUNEL/Propidium iodide kit. As the 1:1000 dilution
of platelet releasate in full growth media was observed to be the
highest concentration of platelet releasate in full media that did not
impact on cell growth/viability for all cell lines and was
subsequently shown to result in no significant difference in
apoptosis compared to cells grown in full media alone it was
determined that it was suitable to proceed with this concentration.
Given that the platelet releasate was prepared from identical
washed platelet preparations, the 1:1000 dilution of platelet
releasate directly informs the use of a 1:1000 dilution of washed
platelets for comparative study. Optimal concentrations of platelet
releasate and washed platelets [1:1000] were suspended in full
culture media and applied to cultured cells in 75 cm
2 flasks in
triplicate. Cells were exposed to releasate or washed platelets for
6 hours after which total RNA was extracted from cells.
Transcriptome analysis was performed using Affymetrix Human
Exon Arrays.
RNA extraction
Cells were washed briefly in PBS, trypsinised and centrifuged to
remove supernatant. RNA was extracted using RNeasy mini kit
[Qiagen Ltd., West Sussex, UK] according to the manufacturer’s
protocol. RNA quantity was assessed using a Nano-Drop ND-
1000 Spectrophotometer [Wilmington, USA] and quality by an
Agilent Bioanalyser 2100 and RNA 6000 Nano microfluidic chip
assay [Santa Clara, USA]. RNA was stored at 280uC.
Affymetrix array
100 ng of total RNA extracted from control cells and cells
exposed to washed platelets/platelet releasate was labelled using
the Ambion WT Expression kit [Ambion/Life Technologies,
Austin, TX, USA] including the labelling controls from the
Affymetrix Gene Chip Poly-A RNA Control Kit. As suggested by
Affymetrix/Ambion, at each step of the sample preparation
protocol, progress was monitored using both the Agilent 2100
Bioanalyzer and the Nanodrop spectrophotometer. Quality
control [QC] required assessment after the first cycle RNA
cleanup, after the second cycle single-strand cDNA cleanup and
following ssDNA fragmentation. Prepared fragmented ssDNA was
hybridised to the Affymetrix Human Exon 1.0 ST Array at 45uC
for 16 hours following Affymetrix protocols for their GeneChip
WT Terminal Labeling, GeneChip Hybridization Control and
GeneChip Hybridization, Wash, and Stain kits [Affymetrix, Santa
Clara, USA]. Following hybridization, the chips were washed and
stained using the Affymetrix GeneChip Fluidics Station with
appropriate 64 format assay protocol. Following staining and
washing steps the Affymetrix GeneChip Scanner 3000 and
Affymetrix GeneChip Operating Software was used for the
management and initial processing of the expression data. The
data from 45 exon arrays was subject to array quality control
performed using the Affymetrix Expression Console. All controls
were within the parameters suggested by Affymetrix. Following
successful quality control standards assessment, the chip data was
then analysed in depth using Biotique Systems XRAY analysis
software. Each cell line was examined under three different
conditions; resting cells, cells exposed to platelet releasate, and cells
exposed to washed platelets. Each cell line and condition was
assayed in triplicate. The software was used to compare the two
exposure cohorts against the resting control and genes exhibiting a
positive or negative fold change of greater than 1.5 and a
significance of p#0.05 examined.
Fluidigm validation
Gene expression was validated using Fluidigm’s high through-
put qPCR 48.48 dynamic array system. Genes displaying the most
significant fold changes in addition to genes involved in
biologically relevant pathways were selected for validation.
TaqManH real-time PCR expression assays were used in
conjunction with Fluidigm’s microfluidic Biomark system. Samples
were analysed in triplicate and results were compared with
Affymetrix expression data. RNA was reverse transcribed to single
stranded cDNA using a High Capacity cDNA RT Kit [Applied
Biosystems, CA, USA] in 100ml reactions. Reactions contained 10
ml of buffer [106], 4 ml of deoxynucleotide triphosphate [256], 10
ml of random primers [106], 5 ml of multiscribe RT enzyme
[50 U/ml], 21 ml of nuclease-free water and 50 ml of extracted total
RNA [20 ng/ml]. Prior to Fluidigm, high throughput qPCR, a
pre-amplification step was performed following Fluidigm proto-
cols; 1 ml of TaqMan assay for each of the genes of interest
identified through XRAY analysis and endogenous controls were
pooled and made to a final volume of 100 ml in 16 TE Buffer,
pH 8.0. 1.25 ml of each sample was added to 2.5 ml Preamp
Platelets and Ovarian Cancer
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reaction volume. This mixture was then subject to 14 amplification
cycles of 95uC, 15 seconds and 60uC, 4 minutes before being
diluted 1:5 with DNAse and RNase free H20 to give a final volume
of 25 ml of pre-amplified cDNA. Fluidigm data was analysed
using Fluidigm Real-Time PCR Analysis software [ver3.02] to
yield relative quantitation values calibrated to normal [HIO-80]
cells. Fold changes returned from Affymetrix analysis were plotted
against those calculated from Fluidigm data and the correlation
between the values was calculated using Graph Pad Prism [ver
5.02].
Epithelial mesenchymal transition [EMT] expression
analysis in platelet cloaked/releasate treated cells
The process of EMT is critical in the metastatic cascade, by
facilitating entry of cells into the vascular system. RNA was reverse
transcribed to single stranded cDNA using a High Capacity cDNA
RT Kit [Applied Biosystems, CA, USA] in 100 ml reactions as
above. A combination of the primary players in the EMT process
[20] and additional genes identified in our laboratory as integral to
the EMT process [data not shown] were examined as part of the
profiling for EMT in ovarian cancer cells: Akt-1, ALDH1 A1,
CDH1, PIK3CA, SNAIL1, SNAIL 2, TWIST 1, VIMENTIN,
ZEB1, ZEB 2, TLR 4, MyD88 using TaqMan primer and probes
[Life Technologies/Applied Biosystems: gene expression assays]
according to the manufacturers instructions. Expression was
examined in platelet and platelet releasate treated cells and
compared with resting ovarian cancer cells for all the cell lines
[HIO-80, 59M, SK-OV-3, A2780 and A2780cis]. Results were
plotted as a volcano plot of p value versus fold change. The
accession assay numbers for the genes examined are shown below:
GAPDH - Hs99999905_m1
AKT1 - Hs00178289_m1
ALDH1A1 - Hs00167445_m1
PIK3CA - Hs00180679_m1
SNAIL1 - Hs00195591_m1
SNAIL2 - Hs00950344_m1
ZEB1 - Hs01566407_m1
ZEB2 - Hs00207691_m1
TWIST - Hs00361186_m1
VIMENTIN - Hs00958116_m1
CDH1 - Hs01023895_m1
MYD88 - Hs00182082_m1
TLR4 - Hs00152939_m1
Statistics
Data were analysed using GraphPad Prism 5.0 software
[GraphPad Software Inc., San Diego, CA, USA]. Results are
expressed as mean 6 standard error of the mean.
Results
Adhesion of platelets to ovarian cancer cells under static
conditions
Platelet adhesion to ovarian cancer cell lines under static
conditions was quantified based on the fluorescent detection of
labelled platelets [Figure 1A]. Platelet adhesion to A2780
[2.460.2%, n=8], A2780cis [3.060.2%, n=8] and 59M
[3.460.3%, n=8] cells was significant compared to the negative
control BSA [1.060.1%, n=8]. Platelet adhesion to HIO-80
[1.860.2%, n=8] and SK-OV-3 [1.360.2%, n=8] cells was not
significant compared to BSA. Adhesion to all 5 ovarian cancer
cells was lower than to the positive control fibrinogen [5.960.4%,
n=8]. Fluorescence microscopy images clearly demonstrate
platelet adhesion to the ovarian cancer cell lines A2780 and
59M [Figure 1B and C]. Consistent with the platelet adhesion
assay, figure S1 demonstrates the minimal platelet adhesion to the
HIO-80 cell line.
Ovarian cancer cells induce platelet activation in a dose
dependent manner
The ability of ovarian cancer cells to induce platelet activation
was quantified by flow cytometry. Increasing concentrations of
ovarian cancer cells [0 – 1.5610
6 cells/ml] were added to PRP
and platelet activation was assessed based on P-selectin expression.
Ovarian cancer cells induced a dose-dependent increase in platelet
activation [Figure 2]. The two metastatic ovarian cancer cell lines;
SK-OV-3 [1.5610
6 cells/ml, 47610.2% of platelets P-selectin
positivity, n=3] and 59M [1.5610
6 cells/ml, 51618% P-selectin
positivity n=6] induced the most significant platelet activation.
Figure 1. Platelet adhesion to a panel of ovarian cancer cell lines is heterogeneous under static conditions. [A] Platelet adhesion to
ovarian cancer cells was quantified based on the fluorescence detection of labelled platelets. Platelet adhesion to fibrinogen and BSA were used as 6
controls [n=8 + SEM, * = p,0.05 vs. BSA]. Fluorescence microscopy images of platelets adhering to A2780 [B] and 59M [C] cells under static
conditions [representative of n=3]. Ovarian cancer cells and platelets were stained for actin [green], platelets were stained specifically for CD42a [red/
yellow].
doi:10.1371/journal.pone.0026125.g001
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metastatic ovarian cancer cell line A2780 [1.5610
6 cells/ml,
16.165.2% P-selectin positivity, n=6]. A2780cis [a cisplatin
resistant daughter cell line to A2780] demonstrated higher platelet
activation than its parent cell line [1.5610
6 cells/ml, 28.1612.2%
P-selectin positivity, n=3]. The immortalised normal ovarian
epithelial cells line HIO-80 also induced platelet activation
[1.5610
6 cells/ml, 32.567.8% of platelets P-selectin positivity,
n=3], but to a lesser extent than 59M and SK-OV-3 cells.
P2Y12/P2Y1 receptor and ADP/ATP antagonists inhibit
platelet activation induced by 59M ovarian cancer cells
Since 59M cells caused the most significant platelet activation,
they were used to test the effect of a range of platelet inhibitors on
ovarian cancer cell induced platelet activation. 59M ovarian
cancer cells [1.5610
6 cells/ml, response normalised to 100%
activation] were added to PRP pre-treated with inhibitors and
platelet activation was measured by flow cytometry [P-selectin
expression]. The concentrations of inhibitors were chosen based
on preliminary flow cytometry and platelet aggregometry results
that showed them to be antagonistic (data not shown). Antagonists
against Thrombin [hirudin], integrin aIIbb3 [Reopro and RGDS
peptide], Cox-1 [aspirin], and calcium [EDTA], had no effect on
59M cell induced platelet activation [Figure 3]. Following
treatment with the P2Y12 antagonist [cangrelor, 1 mM], the
P2Y1 antagonist [MRS2179, 10 mM] or the ADP/ATPase
(apyrase, 10 units/ml), platelet activation in the presence of 59M
ovarian cancer cells was significantly diminished [1 mM Cangrelor
- 92.460.64% inhibition, p,0.001; 10 mM MRS2179 –
71.4610.52% inhibition, p=0.01; 10 units/ml apyrase,
91.863.7% inhibition, p,0.001]. This suggests an ADP depen-
dent mechanism of platelet activation by 59M cells, potentially
mediated by the release of ADP by the cells into their supernatant
[Figure 3].
Ovarian cancer cells potentiate TRAP [thrombin receptor
activating peptide], PAR 4 agonist, and arachidonic acid
induced platelet activation in a dose dependent manner
Since thrombosis is a complex process that involves multiple
agonists in vivo, we next asked if ovarian cancer cells modulated
agonist [TRAP, PAR 4 agonist, Arachidonic Acid, ADP,
epinephrine, and Collagen] induced platelet activation. To
Figure 2. Ovarian cancer cell lines induce platelet activation in a dose dependent manner [n=3–6, ± SEM]. Platelet activation [P-
selectin expression] induced by a range of ovarian cell lines over a large concentration range [0.1–1.5610
6/ml] was measured by flow cytometry,
based on platelet P-selectin surface expression. The most significant platelet activation was seen in response to the metastatic ovarian cancer cell
lines SK-OV-3 and 59M.
doi:10.1371/journal.pone.0026125.g002
Figure 3. 59M tumour cell induced platelet activation (TCIPA) is
inhibited by cangrelor, MRS2179, and apyrase. This suggests a
mechanism of platelet activation dependant on the platelet receptors
P2Y12 and P2Y1, and ADP released by 59M cells into their supernatant.
Other platelet antagonists such as hirudin, EDTA, abciximab, RGDS, and
aspirin had no effect on 59M cell induced platelet activation.
doi:10.1371/journal.pone.0026125.g003
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with low ovarian cancer cell concentrations and low agonist
concentrations. Platelet agonist concentrations that gave #20%
platelet activation [P-selectin expression] were used. At low
cellular concentrations [0.5–1610
5 cells/ml], 59M ovarian cancer
cells potentiated PAR-1 [TRAP], PAR-4 [PAR4 agonist] and
TxA2 receptor [Arachidonic Acid] mediated platelet activation [P-
selectin expression], but had no effect on ADP, epinephrine, or
collagen induced activation [Figure 4]. For example, in response
to 1 mM TRAP and 1610
5 59M cells/ml, platelet activation was
44612.16% P-selectin positivity [n=3, Figure 3] compared to
4.461.6% P-selectin positivity [1610
5 59M cells/ml alone, n=3]
and 5.161.3% P-selectin positivity [1 mM TRAP alone, n=3].
Conversely, in response to 1 mM ADP and 1610
5 59M cells/ml,
platelet activation was 17.366.2% P-selectin positivity [n=3,
Figure 4] compared to 2.461.4% [1610
5 59M cells/ml alone,
n=3] and 14.7365.3% [1 uM ADP alone, n=3]. Similar results
are also seen in response to A2780 cells [1 – 5610
5 cells/ml], but
higher A2780 cell concentrations were required to induce a similar
effect to 59M cells [data not shown]. The data suggests a
synergistic relationship between PAR-1, PAR4, and TxA2
receptor mediated platelet activation and A2780/59M induced
platelet activation. This synergistic interaction is also inhibited by
the P2Y12 antagonist cangrelor [data not shown].
Expression array analysis of ovarian cancer cells treated
with washed platelets or platelet releasate using
Affymetrix exon arrays
AllarrayspassedQCusingAffymetrixQCsoftware.BiotiquesX-
Ray software plug-in for Microsoft Excel was used to interrogate
gene expression changes between treatments and cell types [Fold
change .1.5and p,0.05].Analytical stringencywas relaxed to fold
changes of .1.5 to accommodate subtle but meaningful biological
variation[p,0.05]thatwascontingent upontreatment.Tables1,2,
3, 4 depict the gene expression variations observed in cells treated
with platelet releasate/washed platelets.
In HIO-80 cells, following treatment with washed platelets or
platelet releasate, seven genes were significantly up-regulated, with
the greatest difference seen in response to washed platelets. The
upregulated genes encode for proteins associated with ovarian
cancer metastasis [SERPINB2/PAI2], metabolic activities [IDI1,
PMM2] and gene expression/transcription [PCGF6, ZNF267].
59M cells also exhibited gene expression changes following
treatment with platelet releasate and washed platelets. The
biological processes affected involved anti-autophagy, anti-apo-
ptotic and pro-angiogenic signalling pathways [TRAF2, CCL2,
TNFAIP2, PDGFb]. Pro-proliferative [HBEGF, CSF2/GMCSF,
IRAK2] immune suppression [CD274/PDL1] anti-apoptotic
[BIRC3/CIAP], cell adhesion and migration [ICAM1] signalling
was also altered in 59M cells treated with platelet releasate.
SK-OV-3 cells exhibited a greater difference in gene expression
following treatment with platelet releasate compared to treatment
with washed platelets. The largest fold change was observed for
the gene encoding for Cardiolipin Synthase [CRLS1] responsible
for cardiolipin [CL] production.
The A2780 cell line and its cisplatin resistant daughter cell line
A2780cis used here as a model for recurrent chemo-resistant
disease returned different responses to treatment with washed
platelets or platelet releasate. The A2780 cell line did not show
significant alteration of gene expression in response to either
treatment. Conversely, the A2780cis cell line revealed a panel of
genes up and down regulated following treatment with washed
platelets but none following treatment with platelet releasate.
Increased expression was observed in genes for cancer associated
proteases [KLK1], cell adhesion/migration molecules [ITGB2/
LFA-1], and reduced expression of genes involved in maintaining
genomic instability [GMNN], inhibition of gene transcription/
expression [CCDC7B, ZNF271, ZNF706, LARP7, RNASEH2B],
pro-apoptotic regulation [STK17B/DRAK2] and immune re-
sponse/evasion [CD58/LFA3].
Validation of gene expression signature by the Fluidigm
48648 dynamic array
Gene expression array results were validated using Fluidigm
high throughput qPCR technology. Twenty five genes were
selected along with two endogenous controls for analysis using
Fluidigm’s 48648 Dynamic Array. The genes selected and the cell
lines and conditions in which significant alteration of expression
were observed by Affymetrix analyses are highlighted in bold in
Tables 1, 2, 3, 4 below. Fold change values for samples revealed
Figure 4. 59M cells potentiate PAR-1, PAR-4, and TxA2 receptor mediated platelet activation. Activation occurs in a dose dependent
manner [n=3, + SEM]. At low concentrations, 59M [0.5–1610
5/ml], cells significantly potentiated TRAP, PAR4 agonist, and Arachidonic acid induced
platelet activation [P-selectin expression]. This suggests a synergistic relationship between PAR-1, PAR-4, and TxA2 receptor mediated platelet
activation and 59M induced platelet activation. Similar results are seen for A2780 cells [1–5610
5 cells/ml, data not shown]
doi:10.1371/journal.pone.0026125.g004
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those genes observed to have undergone altered expression in the
59M, SK-OV-3 and A2780cis cell lines [Figure 5A, B, C, D].
Discrepancies between expression calculated by Affymetrix and
TaqMan analyses are likely due to normalisation and summarisa-
tion methods. The expression score for each probeset for the
arrays is derived using the standard Robust Multiarray Averaging
[RMA] normalisation and summarisation methods. The RMA
algorithm was used because compared to other approaches, it
increases sensitivity to small changes between experiment and
control samples and minimses variance across dymanic range, but
in doing so it does compress calculated fold change values. This
means generally the fold change value obtained with the
affmetrixy array is smaller than that obtained with the TaqMan
assay. The correlation for genes observed to undergo significant
alteration of expression in both the normal [immortalised] HI0-80
and malignant 59M ovarian carcinoma cell lines was high [.0.8]
and was statistically significant [p,0.05]. Figure 6 summarises the
findings of the gene expression analysis.
Expression analysis of EMT associated genes in ovarian
cancer cells exposed to platelet releasate
EMT profiling was performed to see if interaction with platelets
would induce EMT. Expression analysis of EMT associated genes
Table 1. Expression data for HIO-80 cells.
Affymetrix Fluidigm
Cell Line Exposure Gene Fold Change Significance (p=) Fold Change Significance (p=)
HIO-80 Platelet Releasate LRP8 1.50 0.0275 1.612 0.0000*
Washed Platelet SERPINB2 1.76 0.0016 1.6909 0.0000*
IDI1 1.70 0.0218
PMM2 1.60 0.0188
PCGF6 1.59 0.0372 1.137 0.0077
CCDC68 1.56 0.0245
ZNF267 1.55 0.0318 1.1571 0.0000*
Data presented according to whether cells directly exposed to platelets or releasate. Genes highlighted in bold were selected for validation. Fluidigm validation fold
change and t-test p values indicated on right.
*p,0.00001.
doi:10.1371/journal.pone.0026125.t001
Table 2. Expression data for 59M cells.
Affymetrix Fluidigm
Cell Line Exposure Gene Fold Change Significance (p=) Fold Change Significance (p=)
59M Platelet Releasate CCL2 1.94 0.0137 2.83 0.0000*
TRAF1 1.92 0.0013 3.50 0.0000*
HBEGF 1.67 0.0034 2.01 0.0000*
CD274 1.64 0.0487 2.09 0.0000*
ANKRD1 1.60 0.0341
TNFAIP2 1.59 0.0018 2.51 0.0000*
BIRC3 1.58 0.0303 1.88 0.0000*
ICAM1 1.57 0.0012
IRAK2 1.56 0.0050
SH2B3 1.53 0.0060 2.20 0.0000*
CSF2 1.52 0.0188
GCH1 1.52 0.0211
HIVEP1 1.51 0.0212
Washed Platelet TRAF1 1.90 0.0056 2.87 0.0000*
CCL2 1.78 0.0281 2.67 0.0000*
TNFAIP2 1.63 0.0048 1.86 0.0000*
PDGFB 1.50 0.0397 2.45 0.0000*
DSN1 -1.60 0.0350 -1.09 0.0036
Data presented according to whether cells directly exposed to platelets or releasate. Genes highlighted in bold were selected for validation. Fluidigm validation fold
change and t-test p values indicated on right.
*p,0.00001.
doi:10.1371/journal.pone.0026125.t002
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associated genes [Figure 7]. Importantly, platelet releasate did not
induce/suppress EMT.
Discussion
The results of the present investigation demonstrate a
differential interaction between platelets and ovarian cancer cell
lines, not only in terms of the effect of ovarian cancer cells on
platelets, but also in the effect of platelets on ovarian cancer cells.
Firstly, we used a panel of ovarian cell lines to assess platelet
adhesion under static conditions. Adhesion across the 5 cells lines
was extremely heterogeneous with significant platelet adhesion to
the 59M, A2780, and A2780cis cell lines, while adhesion to the
HI0-80 and SK-OV-3 cell lines was not significant compared to
the BSA negative control [Figure 1]. The adhesion of platelets to
all ovarian cancer cell lines was significantly less than to
fibrinogen, suggesting that the adhesion is mediated by either a
lower copy number receptor-ligand interaction, or a lower affinity
interaction than platelet integrin aIIbb3 mediated adhesion to
fibrinogen. The molecular mechanisms mediating platelet adhe-
sion to ovarian cancer cells remains to be elucidated. Secondly, we
assessed the ability of ovarian cancer cells to induce platelet
activation. We found that ovarian cancer cells induce platelet
activation and degranulation in a dose dependent manner with the
most significant platelet activation seen in response to the 59M
and SK-OV-3 ovarian cancer cell lines [Figure 2].
Using 59M cells we then investigated the effect of different
platelet inhibitors to determine the mechanism of ovarian cancer
cell induced platelet activation. Following treatment with can-
grelor [P2Y12 antagonist], MRS2179 [P2Y1 antagonist], or
apyrase [ADP/ATPase], platelet activation in the presence of
59M ovarian cancer cells was greatly diminished, suggesting a
P2Y12/P2Y1 dependent mechanism of activation, mediated by
the release of ADP by 59M cells, as the 59M cell supernatant
induced comparable platelet activation [Figure 3]. Consistent with
the literature, other studies have also demonstrated ADP
dependent platelet aggregation induced by cancer cells [21]. Of
note, Uluckan et al have shown that treatment with APT102 [an
ADPase] and aspirin in combination, inhibited B16 melanoma cell
induced aggregation, and decreased metastasis in a murine B16
melanoma model of bone metastasis [22]. Italiano et al have
previously shown that platelets differentially package angiogenic
regulatory proteins in separate alpha granules that are subject to
differential release depending on the platelet agonist [23].
Interestingly, Bambace et al have demonstrated that ADP induced
platelet activation causes the release of VEGF [pro-angiogenic]
but not endostatin [anti-angiogenic] in vitro [24], indicating a
potential mechanism by which ovarian cancer cells could induce
the release of pro-angiogenic but not anti-angiogenic factors by
platelets in vivo.
Ovarian cancer cells alone induce activation of platelets.
However, thrombosis is a complex process that involves many
different agonists in vivo. Therefore, we examined how ovarian
cancer cells modulate agonist induced platelet activation. At low
cellular concentrations, both A2780 and 59M cells potentiate
TRAP, PAR-4 agonist, and arachidonic acid induced platelet
activation, but not ADP, epinephrine, or collagen induced platelet
activation [Figure 4]. This suggests a synergistic relationship
between PAR-1/PAR-4/TxA2 receptor mediated activation and
the mode of ovarian cancer cell induced activation. Thrombin is
the physiological ligand for the PAR-1 and PAR-4 receptors, and
its generation is critical for coagulation. The expression of
thrombin has been identified in ovarian cancer tissue [25] and is
known to potentiate invasion in an in vitro model of ovarian cancer
[26]. Holmes et al have also shown that TRAP treated platelets
Table 3. Expression data for SK-OV-3 cells.
Affymetrix Fluidigm
Cell Line Exposure Gene Fold Change Significance (p=) Fold Change Significance (p=)
SK-OV-3 Platelet Releasate CRLS1 1.91 0.0346 -1.09 0.0338
UBLCP1 1.82 0.0256
RPL7A 1.72 0.0290
AK3 1.66 0.0432
MGC71993 1.66 0.0299
ANXA2 1.64 0.0225 1.04 0.3191
KIAA1324 1.58 0.0417 -1.05 0.1362
PCNP 1.52 0.0455
SLC9A8 1.52 0.0480
TPM4 1.51 0.0356
ACTL6A 1.51 0.0380
C14ORF153 1.50 0.0190
MUS81 1.50 0.0222 -1.09 0.0809
CRIPAK -1.55 0.0105 -1.23 0.0007
ISOC2 -1.69 0.0036 -1.09 0.0000*
VPS26B -1.69 0.0402 -1.03 0.5467
Washed Platelet ASTN1 1.58 0.0030 -1.03 0.9001
Data presented according to whether cells directly exposed to platelets or releasate. Genes highlighted in bold were selected for validation. Fluidigm validation fold
change and t-test p values indicated on right.
*p,0.00001.
doi:10.1371/journal.pone.0026125.t003
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is also increased in ovarian cancer, with a trend towards higher
fold increases in pro-aggregatory TxA2 levels compared to anti-
aggregatory PGI2 levels [28].
Having established that ovarian cancer cells interact with
platelets, we next assessed the effect of platelet adhesion and
platelet granule release on ovarian cancer cells. Overall analysis of
gene expression changes in ovarian cancer cells following
treatment with washed platelets or platelet releasate showed an
upregulation of anti-apoptotic, anti-autophagy, pro-angiogenic,
pro-cell cycle and metabolic genes in the treated ovarian cancer
cells [Tables 1, 2, 3, 4]. However, ovarian cancer cells of variable
phenotype showed differential gene expression profiles, possibly
related to their underlying biology.
In HIO-80 cells, there was significant upregulation of genes
encoding for proteins associated with ovarian cancer metastasis
[SERPINB2/PAI2], metabolic activities [IDI1, PMM2] and gene
expression/transcription [PCGF6, ZNF267] [29]. LRP8
[ApoER2] which showed significantly increased expression in
response to platelet releasate exposure was also observed to be up
regulated in response to washed platelet exposure and its
activation has been observed to alter migratory capability in a
non-tumorigenic breast epithelial [MCF 10A] cell model [30]. It
also has a key role in mediating increased platelet activation and
adhesion in association with other glycoproteins or clotting factors
[31–34] and may promote signalling in cells via ApoER2. HIO-80
are a non-tumorigenic normal human ovarian surface epithelial
cell line, which has been immortalised by transfection with a
plasmid encoding for the SV40 large T gene. SERPINB2/PAI2
was the most significantly upregulated gene on validation and this
upregulation may be explained by the fact that platelets can
release TNFa [35] which in turn has been shown to induce matrix
Table 4. Expression data for A2780cis cells.
Affymetrix Fluidigm
Cell Line Exposure Gene Fold Change Significance (p=) Fold Change Significance (p=)
A2780cis Washed Platelet KLK1 1.63 0.0239 1.44 0.0309
ITGB2 1.52 0.0497 1.23 0.0000*
ABCD3 -1.50 0.0431
RMND1 -1.50 0.0335
ARL15 -1.50 0.0137
RAD18 -1.51 0.0327
CAPZA1 -1.51 0.0324
SPAST -1.52 0.0200
C11ORF54 -1.53 0.0316
MAD2L1 -1.53 0.0407
MRPL33 -1.53 0.0328
RNASEH2B -1.53 0.0384
DAB1 -1.54 0.0204
SMCHD1 -1.54 0.0359
DPY19L4 -1.56 0.0383
EIF2B3 -1.56 0.0310
C1ORF112 -1.56 0.0305
ZNF271 -1.56 0.0131
VGLL3 -1.56 0.0115
NDUFAF1 -1.58 0.0443
LARP7 -1.58 0.0400
SNRPA1 -1.59 0.0276
MED10 -1.60 0.0114
PTBP2 -1.60 0.0337
STK17B -1.61 0.0304 1.13 0.0019
PRIM2A -1.62 0.0464
GMNN -1.67 0.0259 1.02 0.4974
ZNF706 -1.68 0.0259
CCDC76 -1.70 0.0263
RP9 -1.71 0.0387
NAP1L4 -1.81 0.0082 -1.19 0.0054
Data presented according to whether cells directly exposed to platelets or releasate. Genes highlighted in bold were selected for validation. Fluidigm validation fold
change and t-test p values indicated on right.
*p,0.00001
doi:10.1371/journal.pone.0026125.t004
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displays some examples of the correlation between the affymetrix array data and the fluidigm validation data. Correlation coefficients are displayed in
the legend.
doi:10.1371/journal.pone.0026125.g005
Figure 6. Summary analysis of gene expression changes due to platelets or platelet releasate. Ovarian cancer cells exposed to platelets
and platelet releasate exhibit a variety of gene expression changes summarised in this figure.
doi:10.1371/journal.pone.0026125.g006
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human ovarian surface epithelial cells providing a molecular
mechanism linking ovulation and ovarian cancer risk [36]
59M cells exhibited aberrant upregulation of genes involved in
anti-autophagy, anti-apoptotic and pro-angiogenic signalling
[TRAF2, CCL2, TNFAIP2] [37–39]. Among the other pathways
showing altered expression were pro-angiogenic signalling through
increased PDGFb transcription in response to washed platelet
exposure with further pro-proliferative [HBEGF, CSF2/GMCSF,
IRAK2] immune suppression [CD274/PDL1] anti-apoptotic
[BIRC3/CIAP], cell adhesion & migration [ICAM1] signalling
[40–44].
SK-OV-3 cells exhibited significant overexpression in the
Cardiolipin Synthase [CRLS1] gene, which is responsible for
cardiolipin [CL] production. Anti-cardiolipin antibodies are
associated with both solid and non-solid tumours and are
associated with increased thrombocytosis [45]. This gene product
[CRLS1] may also have an anti-apoptotic role as reduced CL
expression is associated with increased apoptosis [46]. Genes
associated with increased cell invasion/motility in breast and
pancreatic cancers [ANXA2] were also dysregulated. Following
treatment with platelet releasate, SK-OV-3 cells also showed
expression changes in genes involved in, anti-autophagy in
endometrial and ovarian cancer [KIAA1324/EIG121], as well
as transcriptional regulation [ACTL6A], cell cycle[MUS81],
cytoskeletal [TPM4] and homeostatic [TPM4] processes [47,48].
The A2780 cell line and its cisplatin resistant daughter cell line
A2780cis displayed different responses to the exposure treatments.
The A2780 cell line did not show significant alteration of gene
expression following treatment with either platelet releasate or
washed platelets. Conversely, the A2780cis cell line revealed a
panel of dysregulated genes following treatment with washed
platelet but none following treatment with platelet releasate.
Increased expression was observed in genes for cancer associated
proteases [KLK1], cell adhesion/migration molecules [ITGB2/
LFA-1], and reduced expression of genes involved in maintaining
genomic instability [GMNN], inhibition of gene transcription/
expression [CCDC7B, ZNF271, ZNF706, LARP7, MASEH2B],
in pro-apoptotic regulators [STK17B/DRAK2] and immune
response/evasion [CD58/LFA3] [49,50].
TaqMan expression analysis of EMT associated genes demon-
strated constitutive expression of the majority of EMT associated
genes [Figure 7]. It appears that EMT related genes are effectively
‘primed’ and that interaction with platelets does not significantly
alter the capacity of cancer cells to mount this type of response.
Other studies have reported similar findings in breast cancer
[51,52].
In summary, our data shows for the first time that there is a
potent dynamic interaction between ovarian cancer cells and
platelets in vitro. This interaction involves platelet adhesion, platelet
activation and degranulation and a resultant pro-survival and pro-
angiogenic signal for the ovarian cancer cell that could potentially
promote ovarian cancer cell metastasis. Further work is required
to determine the significance of this interaction in vivo.
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